期 |
栏目 |
标题 |
文件 |
卷 93, 编号 4 (2021) |
Reviews |
Exocrine pancreas insufficiency: clinical significance and approaches to correction from evidence medicine |
(Rus)
|
卷 93, 编号 8 (2021) |
Editorial |
Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management |
(Rus)
|
卷 93, 编号 8 (2021) |
Original articles |
Prevalence and prognostic value of gastroenterological manifestations of COVID-19: data from the Russian University Clinic |
(Rus)
|
卷 93, 编号 8 (2021) |
Original articles |
Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study |
(Rus)
|
卷 93, 编号 12 (2021) |
Original articles |
Complex assessment of esophageal acidification and motor function in patients with Barrett's esophagus on antisecretory therapy |
(Rus)
|
卷 93, 编号 11 (2021) |
Original articles |
Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis |
(Rus)
|
卷 94, 编号 1 (2022) |
Original articles |
Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia |
(Rus)
|
卷 94, 编号 2 (2022) |
Original articles |
The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus |
(Rus)
|
卷 94, 编号 8 (2022) |
GUIDELINES |
Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians |
(Rus)
|
卷 94, 编号 8 (2022) |
Original articles |
Composition of oropharyngeal microbiota in patients with COVID-19 of different pneumonia severity |
(Rus)
|
卷 94, 编号 8 (2022) |
Clinical notes |
Masks hiding mitochondrial neurogastrointestinal encephalomyopathy. Case report |
(Rus)
|
卷 94, 编号 9 (2022) |
Original articles |
Prevalence of combination of functional dyspepsia and irritable bowel syndrome: a meta-analysis of studies using the Rome III–IV Criteria |
(Rus)
|
卷 94, 编号 10 (2022) |
Original articles |
Efficacy of Saccharomyces boulardii CNCM I-745 probiotic drug in the prevention and treatment of diarrhea in hospitalized patients with new coronavirus infection COVID-19 |
(Rus)
|
卷 94, 编号 11 (2022) |
Reviews |
Liver disease during the pandemic of COVID-19 infection: prediction of the course and tactics of management: A review |
(Rus)
|
卷 94, 编号 12 (2022) |
Original articles |
Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: a systematic review and meta-analysis of controlled trials |
(Rus)
|
卷 94, 编号 12 (2022) |
Original articles |
Treatment of toxic hepatitis in COVID-19 patients |
(Rus)
|
卷 95, 编号 1 (2023) |
Original articles |
Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study |
(Rus)
|
卷 95, 编号 2 (2023) |
Original articles |
Effectiveness of empirical Helicobacter pylori eradication therapy with furazolidone in Russia: results from the European Registry on Helicobacter pylori Management (Hp-EuReg) |
(Rus)
|
卷 95, 编号 2 (2023) |
Original articles |
Comparative analysis of the intestinal microbiota in patients with exocrine pancreatic insufficiency of various severity |
(Rus)
|
卷 95, 编号 7 (2023) |
Reviews |
Diseases of the gastrointestinal tract in the context of COVID-19 infection: present and future challenges: A review |
(Rus)
|
卷 95, 编号 8 (2023) |
Editorial |
Drug-induced liver injury: diagnosis of exclusion |
(Rus)
|
卷 95, 编号 8 (2023) |
Original articles |
Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy |
(Rus)
|
卷 95, 编号 8 (2023) |
Reviews |
Current status and prospects of using the prokinetic acotiamide in gastroenterology: A review |
(Rus)
|
卷 95, 编号 12 (2023) |
Reviews |
Inflammatory bowel diseases: Transformation of representations. A review |
(Rus)
|
卷 95, 编号 12 (2023) |
Editorial |
Study of the resistome of human microbial communities using a targeted panel of antibiotic resistance genes in COVID-19 patients |
(Rus)
|
卷 96, 编号 2 (2024) |
Consensuns |
Resolution of the Expert Forum "New therapeutic horizons of NAFLD" |
(Rus)
|